DE69716602T2 - Substituierte 3,5-diphenyl-1,2,4-triazole und ihre verwenung als pharmazeutischemetallchelatoren - Google Patents

Substituierte 3,5-diphenyl-1,2,4-triazole und ihre verwenung als pharmazeutischemetallchelatoren

Info

Publication number
DE69716602T2
DE69716602T2 DE69716602T DE69716602T DE69716602T2 DE 69716602 T2 DE69716602 T2 DE 69716602T2 DE 69716602 T DE69716602 T DE 69716602T DE 69716602 T DE69716602 T DE 69716602T DE 69716602 T2 DE69716602 T2 DE 69716602T2
Authority
DE
Germany
Prior art keywords
lower alkyl
bis
hydroxyphenyl
triazol
hydroxy
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
DE69716602T
Other languages
German (de)
English (en)
Other versions
DE122007000020I1 (de
DE69716602D1 (de
Inventor
Pierre Acklin
Rene Lattmann
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Novartis AG
Original Assignee
Novartis AG
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=4214048&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=DE69716602(T2) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Novartis AG filed Critical Novartis AG
Priority to DE122007000020C priority Critical patent/DE122007000020I2/de
Application granted granted Critical
Publication of DE69716602D1 publication Critical patent/DE69716602D1/de
Publication of DE69716602T2 publication Critical patent/DE69716602T2/de
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D249/00—Heterocyclic compounds containing five-membered rings having three nitrogen atoms as the only ring hetero atoms
    • C07D249/02—Heterocyclic compounds containing five-membered rings having three nitrogen atoms as the only ring hetero atoms not condensed with other rings
    • C07D249/08—1,2,4-Triazoles; Hydrogenated 1,2,4-triazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P39/00—General protective or antinoxious agents
    • A61P39/04—Chelating agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/06—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Toxicology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
DE69716602T 1996-06-25 1997-06-24 Substituierte 3,5-diphenyl-1,2,4-triazole und ihre verwenung als pharmazeutischemetallchelatoren Expired - Lifetime DE69716602T2 (de)

Priority Applications (1)

Application Number Priority Date Filing Date Title
DE122007000020C DE122007000020I2 (de) 1996-06-25 1997-06-24 Substituierte 3,5-diphenyl-1,2,4-triazole und ihre verwendung als pharmazeutische metallchelatoren

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
CH159396 1996-06-25
PCT/EP1997/003315 WO1997049395A1 (en) 1996-06-25 1997-06-24 Substituted 3,5-diphenyl-1,2,4-triazoles and their use as pharmaceutical metal chelators

Publications (2)

Publication Number Publication Date
DE69716602D1 DE69716602D1 (de) 2002-11-28
DE69716602T2 true DE69716602T2 (de) 2003-06-26

Family

ID=4214048

Family Applications (3)

Application Number Title Priority Date Filing Date
DE69716602T Expired - Lifetime DE69716602T2 (de) 1996-06-25 1997-06-24 Substituierte 3,5-diphenyl-1,2,4-triazole und ihre verwenung als pharmazeutischemetallchelatoren
DE122007000020C Active DE122007000020I2 (de) 1996-06-25 1997-06-24 Substituierte 3,5-diphenyl-1,2,4-triazole und ihre verwendung als pharmazeutische metallchelatoren
DE1997616602 Pending DE122007000020I1 (de) 1996-06-25 1997-06-24 Substituierte 3,5-diphenyl-1,2,4-Triazole und ihreVerwenung als Pharmazeutischemetallchelatoren

Family Applications After (2)

Application Number Title Priority Date Filing Date
DE122007000020C Active DE122007000020I2 (de) 1996-06-25 1997-06-24 Substituierte 3,5-diphenyl-1,2,4-triazole und ihre verwendung als pharmazeutische metallchelatoren
DE1997616602 Pending DE122007000020I1 (de) 1996-06-25 1997-06-24 Substituierte 3,5-diphenyl-1,2,4-Triazole und ihreVerwenung als Pharmazeutischemetallchelatoren

Country Status (36)

Country Link
US (3) US6465504B1 (OSRAM)
EP (1) EP0914118B1 (OSRAM)
JP (1) JP3541042B2 (OSRAM)
KR (1) KR100616378B1 (OSRAM)
CN (1) CN1146415C (OSRAM)
AP (1) AP1127A (OSRAM)
AR (1) AR007479A1 (OSRAM)
AT (1) ATE226435T1 (OSRAM)
AU (1) AU718037B2 (OSRAM)
BG (1) BG64248B1 (OSRAM)
BR (1) BR9709973A (OSRAM)
CA (1) CA2255951C (OSRAM)
CY (2) CY2429B1 (OSRAM)
CZ (1) CZ291470B6 (OSRAM)
DE (3) DE69716602T2 (OSRAM)
DK (1) DK0914118T3 (OSRAM)
ES (1) ES2187785T3 (OSRAM)
FR (1) FR06C0049I2 (OSRAM)
GE (1) GEP20084355B (OSRAM)
HU (1) HU226232B1 (OSRAM)
IL (1) IL127212A0 (OSRAM)
LT (1) LTC0914118I2 (OSRAM)
LU (1) LU91291I2 (OSRAM)
MY (1) MY129541A (OSRAM)
NL (1) NL300248I2 (OSRAM)
NO (3) NO317180B1 (OSRAM)
NZ (1) NZ333308A (OSRAM)
OA (1) OA10946A (OSRAM)
PL (1) PL194758B1 (OSRAM)
PT (1) PT914118E (OSRAM)
RU (1) RU2208010C2 (OSRAM)
SI (1) SI0914118T1 (OSRAM)
SK (1) SK284319B6 (OSRAM)
TR (1) TR199802693T2 (OSRAM)
TW (1) TW533205B (OSRAM)
WO (1) WO1997049395A1 (OSRAM)

Families Citing this family (109)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6677487B2 (en) 2001-08-30 2004-01-13 Pharmacia Corporation α-haloenamine reagents
GB0126618D0 (en) * 2001-11-06 2002-01-02 Novartis Ag Organic compounds
ES2192494B1 (es) * 2002-03-27 2005-02-16 Consejo Superior De Investigaciones Cientificas Derivados de 1,2,4-triazol con propiedades cannabinoides.
US8829198B2 (en) * 2007-10-31 2014-09-09 Proteotech Inc Compounds, compositions and methods for the treatment of beta-amyloid diseases and synucleinopathies
GB0223978D0 (en) * 2002-10-15 2002-11-20 Novartis Ag Organic compound
MY142651A (en) * 2003-03-18 2010-12-15 Merck Sharp & Dohme Biaryl substituted triazoles as sodium channel blockers
US20050008699A1 (en) * 2003-07-11 2005-01-13 Fred Wehling Effervescent glucosamine composition
US20090074890A1 (en) * 2003-11-10 2009-03-19 Park Min K Substituted Triazoles as Sodium Channel Blockers
JP2007514699A (ja) * 2003-12-19 2007-06-07 ノバルティス アクチエンゲゼルシャフト （ａ）Ｎ−｛５−［４−（４−メチル−ピペラジノ−メチル）−ベンゾイルアミド］−２−メチルフェニル｝−４−（３−ピリジル）−２−ピリミジン−アミンおよび（ｂ）少なくとも１個のハイプシン化阻害剤を含む組み合わせ物およびその使用
GB0408078D0 (en) * 2004-04-08 2004-05-12 Novartis Ag Organic compounds
US9737511B2 (en) * 2004-05-24 2017-08-22 Geoffrey C. GURTNER Method of treating or preventing pathologic effects of acute increases in hyperglycemia and/or acute increases of free fatty acid flux
WO2005115379A2 (en) * 2004-05-24 2005-12-08 New York University Method of treating or preventing pathologic effects of acute increases in hyperglycemia and/or acute increases of free fatty acid flux
MX2007009135A (es) * 2005-01-28 2007-09-06 Novartis Ag Uso de pirimidilaminobenzamidas para el tratamiento de enfermedades que responden a la modulacion de la actividad de la cinasa tie-2.
EP1853235A1 (en) * 2005-02-10 2007-11-14 Novartis AG Methods for improving drug disposition
US20080199428A1 (en) * 2005-05-31 2008-08-21 Alberti Daniele M Treatment of Liver Diseases in Which Iron Plays a Role in Pathogenesis
JP2009512652A (ja) * 2005-10-19 2009-03-26 ノバルティス アクチエンゲゼルシャフト 安息香酸誘導体含有分散錠
EP1945272B1 (en) * 2005-11-01 2013-09-11 Novartis AG Method of scintigraphy
JP5035752B2 (ja) * 2006-02-03 2012-09-26 大正製薬株式会社 トリアゾール誘導体
NZ572299A (en) * 2006-05-09 2010-07-30 Novartis Ag Combination comprising a substituted 3,5-diphenyl-1,2,4-triazole and a platinum compound and use thereof
MX2008014837A (es) * 2006-05-23 2008-12-01 Novartis Ag Metodo para el tratamiento de hemocromatosis hereditaria.
TWI448285B (zh) * 2006-07-13 2014-08-11 Los Angeles Biomed Res Inst 用以治療白黴菌症（ｍｕｃｏｒｍｙｃｏｓｉｓ）及其他真菌類疾病之組合物及方法
EP2049108A1 (en) * 2006-08-04 2009-04-22 Novartis AG Treatment of endocrine dysfunction using iron chelators
RU2339625C2 (ru) * 2006-11-02 2008-11-27 Российский химико-технологический университет (РХТУ им. Д.И. Менделеева) ЗАМЕЩЕННЫЕ N-[ω-АЗОЛ-1-ИЛ)АЛКИЛ]БЕНЗОЛСУЛЬФАМИДЫ В КАЧЕСТВЕ СРЕДСТВ С АНТИАГРЕГАЦИОННОЙ АКТИВНОСТЬЮ И СПОСОБЫ ИХ ПОЛУЧЕНИЯ
KR20150046369A (ko) 2006-11-29 2015-04-29 노파르티스 아게 데페라시록스 (ｉｃｌ６７０ａ)의 다형체 형태
EP1927591A1 (en) * 2006-11-29 2008-06-04 Novartis AG Polymorphic Forms of Deferasirox (ICL670)
EP2108013A2 (en) * 2007-01-29 2009-10-14 Teva Gyógyszergyár Zártköruen Muködo Részvénytársaság Crystalline forms of deferasirox
MX2009012375A (es) * 2007-05-14 2009-12-01 Novartis Ag Uso de quelante del hierro para el tratamiento del infarto de miocardio.
EP1994930A1 (en) * 2007-05-22 2008-11-26 Novartis AG Triazol compounds for treating biofilm formation
WO2009016359A1 (en) * 2007-07-27 2009-02-05 Pliva Hrvatska D.O.O. New forms of deferasirox
US20090082412A1 (en) * 2007-09-26 2009-03-26 Protia, Llc Deuterium-enriched deferasirox
US20090142395A1 (en) 2007-11-19 2009-06-04 Uri Zadok Deferasirox pharmaceutical compositions
CZ301873B6 (cs) 2008-01-30 2010-07-14 Farmak, A. S. Zpusob prípravy kyseliny 4-[3,5-bis(2-hydroxyfenyl)-[1,2,4]triazol-1-yl]benzoové
WO2009106824A2 (en) * 2008-02-25 2009-09-03 Cipla Limited Pharmaceutical formulations
WO2009111611A2 (en) 2008-03-05 2009-09-11 Proteotech Inc. Compounds, compositions and methods for the treatment of islet amyloid polypeptide (iapp) accumulation in diabetes
WO2009130604A2 (en) * 2008-04-21 2009-10-29 Actavis Group Ptc Ehf Solid state forms of deferasirox salts and process for the preparation thereof
WO2009147529A1 (en) * 2008-06-02 2009-12-10 Actavis Group Ptc Ehf Substantially pure deferasirox and processes for the preparation thereof
JPWO2010032489A1 (ja) 2008-09-22 2012-02-09 国立大学法人旭川医科大学 鉄キレート剤及びその製造方法、並びに鉄イオンの定量・捕捉方法
US10098857B2 (en) 2008-10-10 2018-10-16 The Board Of Trustees Of The Leland Stanford Junior University Topical and transdermal delivery of HIF-1 modulators to prevent and treat chronic wounds
WO2010092419A1 (en) 2009-02-12 2010-08-19 Assistance Publique - Hopitaux De Paris Combined treatment of multiple sclerosis
CA2755273A1 (en) 2009-03-19 2010-09-23 Los Angeles Biomedical Research Institute At Harbor-Ucla Medical Center Vaccine compositions and methods for treatment of mucormycosis and other fungal diseases
IT1398770B1 (it) * 2009-07-22 2013-03-18 Bellacchio Oligonucleotidi attivabili mediante l'appaiamento con sequenze di acidi nucleici e loro uso
WO2011021218A2 (en) * 2009-08-12 2011-02-24 Msn Laboratories Limited Process for the preparation of 4-[3,5-bis(2-hydroxyphenyl)-1h-1,2,4-triazol-1-yl]-benzoic acid and its amine salts
US8772503B2 (en) 2009-12-07 2014-07-08 Mapi Pharma Ltd. Processes for the preparation of deferasirox, and deferasirox polymorphs
KR20130041144A (ko) 2010-07-08 2013-04-24 라티오팜 게엠베하 데페라시록스의 경구투여용 제제
US8907083B2 (en) * 2010-08-25 2014-12-09 Ramamohan Rao Davuluri Process for the preparation, of 2-(2-hydroxyphenyl)-benz [1, 3] oxazin-4-one and its use for preparation of 4-[3, 5-bis (2-hydroxyphenyl)-IH-I, 2, 4-triazolTI-yl] benzoic acid
NZ608380A (en) * 2010-10-01 2014-10-31 Cipla Ltd Pharmaceutical composition comprising deferasirox
EP2643306B1 (en) * 2010-11-24 2015-09-23 Alembic Pharmaceuticals Limited Process for the preparation of deferasirox
WO2012096183A1 (ja) 2011-01-14 2012-07-19 株式会社ダステック 高分子鉄キレート剤
US20140276107A1 (en) 2011-10-14 2014-09-18 Photocure Asa Photodynamic diagnosis
US20140316534A1 (en) 2011-10-14 2014-10-23 Photocure Asa Stent
US8822464B2 (en) 2011-11-28 2014-09-02 Boehringer Ingelheim International Gmbh N-aryl-piperazine derivatives and their use as positive allosteric modulators of mGluR5 receptors
US8741892B2 (en) 2011-12-05 2014-06-03 Boehringer Ingelheim International Gmbh Compounds
US8642774B2 (en) * 2011-12-08 2014-02-04 Boehringer Ingelheim International Gmbh Compounds
US8796467B2 (en) 2011-12-13 2014-08-05 Boehringer Ingelheim International Gmbh Compounds
US8846948B2 (en) 2011-12-13 2014-09-30 Boehringer Ingelheim International Gmbh Compounds
US8883789B2 (en) 2011-12-14 2014-11-11 Boehringer Ingelheim International Gmbh Piperazine derivatives and their use as positive allosteric modulators of mGluR5 receptors
US8716277B2 (en) 2011-12-14 2014-05-06 Boehringer Ingelheim International Gmbh Substituted imidazole compounds useful as positive allosteric modulators of mGlu5 receptor activity
US8937176B2 (en) 2011-12-14 2015-01-20 Boehringer Ingelheim International Gmbh Compounds
US8889677B2 (en) 2012-01-17 2014-11-18 Boehringer Ingellheim International GmbH Substituted triazoles useful as mGlu5 receptor modulators
US9593086B2 (en) * 2013-03-06 2017-03-14 Biocon Limited Process for the preparation of deferasirox
WO2014136079A1 (en) 2013-03-08 2014-09-12 Novartis Ag Oral formulations of deferasirox
JP2016518398A (ja) * 2013-05-10 2016-06-23 シプラ・リミテッド 低用量医薬組成物
DE102013217390A1 (de) 2013-09-02 2015-03-05 Henkel Ag & Co. Kgaa Wasch- und Reinigungsmittel mit verbesserter Leistung
CN103454370B (zh) * 2013-09-11 2014-12-24 中美华世通生物医药科技（武汉）有限公司 一种利用hplc测定原料药中苯肼类化合物残留的方法
JOP20200094A1 (ar) 2014-01-24 2017-06-16 Dana Farber Cancer Inst Inc جزيئات جسم مضاد لـ pd-1 واستخداماتها
JOP20200096A1 (ar) 2014-01-31 2017-06-16 Children’S Medical Center Corp جزيئات جسم مضاد لـ tim-3 واستخداماتها
LT3116909T (lt) 2014-03-14 2020-02-10 Novartis Ag Antikūno molekulės prieš lag-3 ir jų panaudojimas
PT2946771T (pt) 2014-05-20 2019-06-27 Sanovel Ilac Sanayi Ve Ticaret As Formulação de comprimido dispersível em água compreendendo deferasirox
EP2987482A1 (en) 2014-08-22 2016-02-24 Santa Farma Ilaç Sanayi A.S. Soluble and dispersible pharamaceutical deferasirox formulation
MA41044A (fr) 2014-10-08 2017-08-15 Novartis Ag Compositions et procédés d'utilisation pour une réponse immunitaire accrue et traitement contre le cancer
EP3206711B1 (en) 2014-10-14 2023-05-31 Novartis AG Antibody molecules to pd-l1 and uses thereof
EP3233918A1 (en) 2014-12-19 2017-10-25 Novartis AG Combination therapies
KR20160088965A (ko) 2015-01-16 2016-07-27 대원제약주식회사 데페라시록스를 함유하는 현탁제
PE20171448A1 (es) 2015-03-10 2017-10-02 Aduro Biotech Inc Composiciones y metodos para activar la senalizacion dependiente del estimulador del gen de interferon
CN104817538A (zh) * 2015-03-13 2015-08-05 东南大学 去铁斯诺-他克林金属离子鳌合剂及其药物用途
WO2016167729A1 (en) 2015-04-16 2016-10-20 Öğün Yusuf Toktamiş Dispersible tablets comprising deferasirox
EP3095443A1 (en) 2015-05-21 2016-11-23 Abdi Ibrahim Ilac Sanayi ve Ticaret A.S. Pharmaceutical composition comprising deferasirox
WO2016203488A1 (en) * 2015-06-16 2016-12-22 Havaldar Freddy H Preparation of novel deferasirox analogues for antimalarial activity
WO2017019897A1 (en) 2015-07-29 2017-02-02 Novartis Ag Combination therapies comprising antibody molecules to tim-3
CN114272371A (zh) 2015-07-29 2022-04-05 诺华股份有限公司 包含抗pd-1抗体分子的联合疗法
EP3317301B1 (en) 2015-07-29 2021-04-07 Novartis AG Combination therapies comprising antibody molecules to lag-3
KR101695970B1 (ko) * 2015-07-31 2017-01-13 건일제약 주식회사 데페라시록스 함유 산제 및 그 제조방법
CN106554770B (zh) * 2015-09-29 2018-10-19 杭州杜易科技有限公司 一种三唑衍生物金属离子荧光探针及其制备方法和应用
HRP20251038T1 (hr) 2015-10-23 2025-11-07 Vifor (International) Ag Novi inhibitori feroportina
ES2986067T3 (es) 2015-12-17 2024-11-08 Novartis Ag Moléculas de anticuerpos frente a PD-1 y usos de las mismas
US20190091204A1 (en) 2016-03-17 2019-03-28 Lupin Limited Compositions of deferasirox
WO2018009466A1 (en) 2016-07-05 2018-01-11 Aduro Biotech, Inc. Locked nucleic acid cyclic dinucleotide compounds and uses thereof
EP3518904A1 (en) 2016-09-30 2019-08-07 Synthon B.V. Pharmaceutical composition comprising deferasirox
JOP20180036A1 (ar) 2017-04-18 2019-01-30 Vifor Int Ag أملاح لمثبطات فروبورتين جديدة
UY37695A (es) 2017-04-28 2018-11-30 Novartis Ag Compuesto dinucleótido cíclico bis 2’-5’-rr-(3’f-a)(3’f-a) y usos del mismo
CZ2017255A3 (cs) 2017-05-04 2018-11-14 Zentiva, K.S. Filmem potažené tablety Deferasiroxu
WO2018208242A1 (en) 2017-05-10 2018-11-15 İlko Ilaç Sanayi Ve Ticaret Anonim Şirketi Formulation of deferasirox tablet for oral suspension composition with better processability
US20200172628A1 (en) 2017-06-22 2020-06-04 Novartis Ag Antibody molecules to cd73 and uses thereof
US11331288B2 (en) 2017-09-14 2022-05-17 The Board Of Trustees Of The Leland Stanford Junior University Conditioning irradiated tissue for increasing vascularity
EP3489692A1 (de) 2017-11-28 2019-05-29 Siemens Healthcare Diagnostics Products GmbH Prothrombinzeit-reagenz enthaltend einen eisenchelator
TR201722910A2 (tr) 2017-12-29 2019-07-22 Sanovel Ilac Sanayi Ve Ticaret Anonim Sirketi Deferasi̇roks i̇çeren suda dağilabi̇len tablet formülasyonlari
KR20190110771A (ko) 2018-03-21 2019-10-01 주식회사 한국팜비오 데페라시록스를 함유하는 소형 분산성 정제
CN108727287B (zh) * 2018-05-10 2020-10-27 东南大学 1,2,4-三唑类化合物及其盐和应用
UY38247A (es) 2018-05-30 2019-12-31 Novartis Ag Anticuerpos frente a entpd2, terapias de combinación y métodos de uso de los anticuerpos y las terapias de combinación
GR1009592B (el) * 2018-07-03 2019-09-11 Φαρματεν Α.Β.Ε.Ε. Φαρμακευτικο σκευασμα που περιλαμβανει εναν χηλικο παραγοντα συμπλεκτικο του σιδηρου και μεθοδος για την παρασκευη αυτου
KR20200113116A (ko) 2019-03-22 2020-10-06 주식회사 한국팜비오 데페라시록스를 포함하는 필름코팅정제
TW202102478A (zh) 2019-04-01 2021-01-16 瑞士商威佛（國際）股份有限公司 新穎的鐵螯合物
EP4031578A1 (en) 2019-09-18 2022-07-27 Novartis AG Entpd2 antibodies, combination therapies, and methods of using the antibodies and combination therapies
IT202000000922A1 (it) 2020-01-20 2021-07-20 Cage Chemicals S R L Complessi di ferro e relativi sali come agenti di contrasto per MRI
US11155547B1 (en) * 2020-06-18 2021-10-26 Alterity Therapeutics Limited Compounds for and methods of treating diseases
WO2022186809A1 (en) 2021-03-05 2022-09-09 Sanovel Ilac Sanayi Ve Ticaret Anonim Sirketi The film coated tablet comprising deferasirox
CN114276305B (zh) * 2021-12-28 2023-11-17 中山大学 一种三取代苯基-1,2,4-三氮唑衍生物及其制备和治疗神经元损伤的应用
CN114478410B (zh) * 2022-03-31 2022-11-29 中山大学 一种二取代苯基-1,2,4-三氮唑衍生物及其制备和应用
CN114591254B (zh) * 2022-03-31 2023-10-13 中山大学 一种3,5-二取代苯基-1,2,4-三氮唑衍生物及其制备方法和应用

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CH388252A (de) 1963-01-24 1964-11-14 Geigy Ag J R Verfahren zum Schützen von Textilmaterial gegen Lichtschädigung
DE2628152C2 (de) 1976-06-23 1985-03-28 Bayer Ag, 5090 Leverkusen Fungizide und nematizide Mittel
US4528196A (en) * 1981-02-23 1985-07-09 The United States Of America As Represented By The Department Of Health And Human Services Chelating agents for the treatment of iron overload
SU1280851A1 (ru) * 1983-07-08 1996-05-27 Ростовский государственный университет 1-фенил-3-алкил-5-(o-оксифенил)-1,2,4-триазолы, обладающие транквилизирующим и антигипоксическим действием, и 1-фенил-3-н-бутил-5-(о-оксифенил)-1,2,4-триазол, обладающий транквилизирующим, антигипоксическим и анальгетическим действием
GB8429307D0 (en) 1984-11-20 1984-12-27 Shell Int Research Heterocyclic herbicides
IL84331A0 (en) * 1987-11-02 1988-04-29 Yissum Res Dev Co Pyridoxyl hydrazone derivatives and pharmaceutical compositions containing the same
US5260322A (en) 1990-10-08 1993-11-09 Merck & Co., Inc. Angiotension II antagonists in the treatment of hyperuricemia
DE4320801A1 (de) * 1993-06-23 1995-01-05 Fahlberg List Pharma Gmbh 2-Hydroxyphenylsubstituierte 1,2,4-Triazole und 1,2,4-Oxadiazole, ihre Verwendung als pharmazeutische Wirkstoffe und sie enthaltende Arzneimittel

Also Published As

Publication number Publication date
SK178598A3 (en) 1999-06-11
CZ427298A3 (cs) 1999-03-17
US6723742B2 (en) 2004-04-20
AU3262997A (en) 1998-01-14
CN1146415C (zh) 2004-04-21
EP0914118A1 (en) 1999-05-12
ES2187785T3 (es) 2003-06-16
HUP9903111A2 (hu) 2000-01-28
LU91291I2 (fr) 2007-01-29
JP2000507601A (ja) 2000-06-20
RU2208010C2 (ru) 2003-07-10
CY2007005I1 (el) 2010-07-28
NL300248I2 (nl) 2007-03-01
ATE226435T1 (de) 2002-11-15
CY2429B1 (en) 2004-11-12
FR06C0049I2 (fr) 2007-04-27
CA2255951C (en) 2006-10-10
IL127212A0 (en) 1999-09-22
CA2255951A1 (en) 1997-12-31
LU91291I9 (OSRAM) 2018-12-27
TR199802693T2 (xx) 1999-05-21
LTPA2007001I1 (lt) 2018-06-25
TW533205B (en) 2003-05-21
FR06C0049I1 (OSRAM) 2007-03-09
US6596750B2 (en) 2003-07-22
AP9801407A0 (en) 1998-12-31
NO2006017I2 (no) 2011-07-04
DK0914118T3 (da) 2003-02-24
US6465504B1 (en) 2002-10-15
LTC0914118I2 (lt) 2018-12-27
PL330119A1 (en) 1999-04-26
DE122007000020I1 (de) 2007-05-24
AP1127A (en) 2002-12-06
BR9709973A (pt) 1999-08-10
KR100616378B1 (ko) 2006-08-28
CN1223579A (zh) 1999-07-21
NO986024L (no) 1998-12-21
MY129541A (en) 2007-04-30
NO986024D0 (no) 1998-12-21
SK284319B6 (sk) 2005-01-03
WO1997049395A1 (en) 1997-12-31
PL194758B1 (pl) 2007-07-31
CZ291470B6 (cs) 2003-03-12
BG64248B1 (bg) 2004-07-30
PT914118E (pt) 2003-02-28
CY2007005I2 (el) 2018-12-12
US20030069273A1 (en) 2003-04-10
NO2018014I1 (no) 2018-04-17
NO2006017I1 (no) 2006-12-18
DE69716602D1 (de) 2002-11-28
SI0914118T1 (en) 2003-04-30
BG103003A (en) 1999-09-30
HK1020530A1 (en) 2000-05-12
HU226232B1 (en) 2008-07-28
NZ333308A (en) 2000-05-26
NL300248I1 (nl) 2007-02-01
AU718037B2 (en) 2000-04-06
OA10946A (en) 2003-02-27
AR007479A1 (es) 1999-10-27
HUP9903111A3 (en) 2000-06-28
US20030203954A1 (en) 2003-10-30
EP0914118B1 (en) 2002-10-23
KR20050098029A (ko) 2005-10-10
JP3541042B2 (ja) 2004-07-07
DE122007000020I2 (de) 2010-12-30
NO317180B1 (no) 2004-09-06
GEP20084355B (OSRAM) 2008-04-29
NO2018014I2 (no) 2018-11-19

Similar Documents

Publication Publication Date Title
DE69716602T2 (de) Substituierte 3,5-diphenyl-1,2,4-triazole und ihre verwenung als pharmazeutischemetallchelatoren
CH690773A5 (de) Pyrrolo(2,3-d)pyrimide und ihre Verwendung.
DE1795062A1 (de) 1H-Imidazo[4,5-b]pyrazin-2-one und Verfahren zu ihrer Herstellung
EP0023594A1 (de) Trans-Chinazolinderivate, Verfahren zu ihrer Herstellung, Zwischenprodukte und Arzneimittel enthaltend solche Chinazolinderivate
DE1946315C2 (de) 4,5-Dihydro-5-oxo-s-triazolo-[1,5-a]-pyrimidin-Derivate, Verfahren zu ihrer Herstellung und sie enthaltende pharmazeutische Zusammensetzungen
DE2648826A1 (de) Triazolderivate
DE60010126T2 (de) Verzweigte substituierte aminoderivate vom 3-amino-1-phenyl-1h(1,2,4)triazol, verfahren zu deren herstellung und sie enthaltende pharmazeutische zusammensetzungen
DE69019294T4 (de) Triazolyl-Hydrazidderivate und Verfahren zu ihrer Herstellung.
KR100568044B1 (ko) 치환된3,5-디페닐-1,2,4-트리아졸및제약학상금속킬레이트화제로서그의용도
EP0110298B1 (de) Acridanon-Derivate
EP0643045A1 (de) Chinolin-Verbindungen als Leukotriene Antagonisten
DE1445438C (OSRAM)
EP0434982B1 (de) 5-(Amino)-triazolylcarbothioamidderivate, Verfahren zu ihrer Herstellung und diese enthaltende Arzneimittel sowie Verwendung der ersteren
HK1020530B (en) Substituted 3,5-diphenyl-1,2,4-triazoles and their use as pharmaceutical metal chelators
DE2607575A1 (de) Triazolocycloalkylhydrothiadiazin- derivate, verfahren zu deren herstellung, sowie dieselben enthaltende pharmazeutische praeparate
EP0024582A1 (de) Benzodiazepinone, Verfahren zu ihrer Herstellung sowie sie enthaltende Arzneimittel
EP0725063A1 (de) Chinolin-Derivate
CH511859A (de) Verfahren zur Herstellung von Pyridazin-dion-Verbindungen
DD295633A5 (de) Neue n-[(heterocyclische)alkyl]-3,4(oder 4,5)-diaryl-1h-pyrazol-1-acetamide oder -propionamide und verfahren zur herstellung